Recombinant
RabMAb

Recombinant Anti-IL-6 antibody [EPR22565-204] (ab233551)

Overview

  • Product name

    Anti-IL-6 antibody [EPR22565-204]
    See all IL-6 primary antibodies
  • Description

    Rabbit monoclonal [EPR22565-204] to IL-6
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, Flow Cyt, IP, ICC/IFmore details
    Unsuitable for: IHC-P
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human IL-6 aa 1 to the C-terminus. The exact sequence is proprietary. HEK-293 expression system.
    Database link: P05231

  • Positive control

    • WB: HUVEC treated with LPS then BFA (Brefeldin A) whole cell lysate. ICC/IF: HUVEC treated with LPS then BFA (Brefeldin A) cells. Flow Cyt: HUVEC treated with LPS then BFA (Brefeldin A) cells. IP: HUVEC treated with LPS then BFA (Brefeldin A) whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab233551 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 21, 28 kDa (predicted molecular weight: 24 kDa).
Flow Cyt 1/400.
IP 1/20.
ICC/IF 1/100.
  • Application notes
    Is unsuitable for IHC-P.
  • Target

    • Function

      Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
    • Involvement in disease

      Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
      Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
    • Sequence similarities

      Belongs to the IL-6 superfamily.
    • Post-translational
      modifications

      N- and O-glycosylated.
    • Cellular localization

      Secreted.
    • Information by UniProt
    • Database links

    • Alternative names

      • Interleukin BSF 2 antibody
      • B cell differentiation factor antibody
      • B cell stimulatory factor 2 antibody
      • B-cell stimulatory factor 2 antibody
      • BSF 2 antibody
      • BSF-2 antibody
      • BSF2 antibody
      • CDF antibody
      • CTL differentiation factor antibody
      • Cytotoxic T cell differentiation factor antibody
      • Hepatocyte stimulating factor antibody
      • Hepatocyte stimulatory factor antibody
      • HGF antibody
      • HSF antibody
      • Hybridoma growth factor antibody
      • Hybridoma growth factor Interferon beta-2 antibody
      • Hybridoma plasmacytoma growth factor antibody
      • IFN-beta-2 antibody
      • IFNB2 antibody
      • IL 6 antibody
      • IL-6 antibody
      • IL6 antibody
      • IL6_HUMAN antibody
      • Interferon beta 2 antibody
      • Interferon beta-2 antibody
      • Interleukin 6 antibody
      • Interleukin 6 (interferon beta 2) antibody
      • Interleukin BSF 2 antibody
      • Interleukin-6 antibody
      see all

    Images

    • All lanes : Anti-IL-6 antibody [EPR22565-204] (ab233551) at 1/1000 dilution

      Lane 1 : Untreated HUVEC (human umbilical vein endothelial cell) whole cell lysate
      Lane 2 : HUVEC treated with 0.5 µg/ml LPS for 4 hours, then 300 ng/ml BFA (Brefeldin A) was added for the last 20 hours, whole cell lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 24 kDa
      Observed band size: 21,24 kDa
      why is the actual band size different from the predicted?



      The molecular weight observed is consistent with what has been described in the literature (PMID: 14970177).

      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (human umbilical vein endothelial cell) cells labeling IL-6 with ab233551 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in HUVEC cells treated with lipopolysaccharide (0.5µg/ml) for 4 h, then together with Brefeldin A (300ng/ml) for another 20h. The nuclear counterstain is DAPI (blue). Counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at a 1/200 dilution (red). The negative control is the secondary antibody only.

    • Flow cytometric analysis of 4% paraformaldehyde-fixed, 90% methanol permeabilized HUVEC (Human umbilical vein endothelial cell) treated with 0.5ug/ml LPS for 4h, then together with 300ng/ml BFA for another 20h (Red) / Untreated control (Green), labeling IL-6 with ab233551 at 1/400 (red) compared with a Rabbit monoclonal IgG (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077), at 1/2000 dilution was used as the secondary antibody.

    • IL-6 was immunoprecipitated from 0.35 mg HUVEC (Human umbilical vein endothelial cell) treated with 0.5µg/ml LPS for 4h, then together with 300ng/ml BFA for another 20h whole cell lysate with ab233551 at 1/20 dilution. Western blot was performed from the immunoprecipitate using ab233551 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used at 1/5000 dilution.

      Lane 1: HUVEC treated as above whole cell lysate 10 µg (Input).

      Lane 2: ab233551 IP in HUVEC treated as above whole cell lysate.

      Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab233551 in HUVEC treated as above whole cell lysate.

      Blocking/Dilution buffer: 5% NFDM/TBST.
      Exposure time: 15 seconds.

    References

    ab233551 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab233551.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up